Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
Stephen J. Nicholls(Australian Centre for Heart Health), Steven E. Nissen(Cleveland Clinic), Jan H. Cornel(Brigham and Women's Hospital), Helina Kassahun(Amgen (United States)), Jingyuan Yang(Amgen (United States)), Ransi Somaratne(Amgen (United States)), Wolfgang Köenig(German Centre for Cardiovascular Research), Jakub Podolec(Jagiellonian University), Leslie Cho(Cleveland Clinic), Antonius Oude Ophuis(Canisius-Wilhelmina Ziekenhuis), Robert C. Scott(Amgen (United States)), Danielle M. Brennan(Center for Clinical Research (United States)), John J.P. Kastelein(QRx Pharma (United States)), Scott M. Wasserman(Amgen (United States)), Rishi Puri(Cleveland Clinic), Todd J. Anderson(University of Calgary), Marilyn Borgman(Cleveland Clinic), Christie M. Ballantyne(Baylor College of Medicine), Imre Ungi(University of Szeged)
Cited by 1,150
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery
|Journal of the American College of Cardiology|2002|4.6k